Logo
x

Search category

Subscribe Now

abbVie

AbbVie Reports Data from the P-III Trial of Atogepant as a Preventive Treatment of Migraine

AbbVie Reports Data from the P-III Trial of Atogepant as a Preventive Treatment of Migraine

  • April 15, 2024
AbbVie Reports the Acquisition of Landos Biopharma for ~$212.5M

AbbVie Reports the Acquisition of Landos Biopharma for ~$212.5M

  • March 26, 2024
Top 20 Women Health Focusing Companies of 2024 Based on Market Cap

Top 20 Women Health Focusing Companies of 2024 Based on Market Cap

  • March 14, 2024
AbbVie and OSE Immunotherapeutics Join Forces for the Development of OSE-230 to Treat Chronic Inflammation

AbbVie and OSE Immunotherapeutics Join Forces for the Development of OSE-230 to Treat Chronic Inflammation

  • February 28, 2024
AbbVie and Tentarix Biotherapeutics Join Forces for the Development of Biologics for Oncology and Immunology

AbbVie and Tentarix Biotherapeutics Join Forces for the Development of Biologics for Oncology and Immunology

  • February 24, 2024
AbbVie and Enigma Biomedical Group (EBG-USA) Enter into a Licensing Agreement to Develop and Commercialize 4R Tau PET Imaging Biomarkers

AbbVie and Enigma Biomedical Group (EBG-USA) Enter into a Licensing Agreement to Develop and Commercialize 4R Tau PET Imaging Biom...

  • January 19, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.